Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma By Ogkologos - June 18, 2025 555 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Nivolumab July 1, 2021 Reflections from our chief scientist: The rise of the whole organism February 4, 2022 Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Load more HOT NEWS Gym Offers Free Membership & Support To Those Struggling With Addiction Longer Duration of Treatment with ICIs Associated with a Higher Rate... EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... EMA Recommends Extension of Indications for Nivolumab
